ORIGINAL RESEARCH article
Front. Oncol.
Sec. Surgical Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1563586
Evaluating the survival outcomes in clinical node stage 2 and 3 breast cancer patients with negative sentinel lymph node biopsy after neoadjuvant chemotherapy: Sentinel lymph node biopsy alone vs. axillary lymph node dissection
Provisionally accepted
- Asan Medical Center, Seoul, Republic of Korea
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
With the advancement of neoadjuvant chemotherapy (NAC), the reliance on surgical removal of axillary for highrisk breast cancer is diminishing. However, there is a lack of data on the oncologic safety of sentinel lymph node biopsy (SNB) alone in patients with clinical node stages 2 and 3 who show a favorable response to NAC. This study aims to compare the oncologic outcomes of SNB alone versus SNB combined with axillary lymph node dissection (ALND) in this patient cohort.Conducted at Asan Medical Center, this retrospective study analyzed data from breast cancer patients treated with NAC between 2008 and 2021. Propensity score matching (PSM) was employed to compare patients based on treatment approach. SNB was performed on patients demonstrating significant response to NAC with minimal nodal involvement and ALND was reserved for cases with negative SNB results, as determined by the operating surgeon. The study evaluated oncologic safety by comparing axillary recurrence-free survival (ARFS), regional recurrence-free survival (RRFS), and overall survival (OS) across surgical methods.Over a median follow-up of 44 months, the overall axillary recurrence rate was 2.3%, and the univariate and multivariate analyses showed no statistically significant differences in ARFS, RRFS, and OS between the groups.Propensity score-matched analysis further confirmed the absence of significant differences in 5-year ARFS, RRFS, and OS outcomes between the SNB-only and ALND groups.This study demonstrates that performing sentinel node biopsy alone is feasible in patients with clinical node stage 2-3 after neoadjuvant chemotherapy. The findings suggest the potential for de-escalation of axillary management in these patients, which could be further explored in follow-up studies.
Keywords: breast cancer, Neoadjuvant chemotherapy, Axillary surgery, Sentinel Lymph Node Biopsy, Axillary lymph node dissection
Received: 20 Jan 2025; Accepted: 21 Apr 2025.
Copyright: © 2025 Shin, Yoo, Kim, Chung, Ko, Kim, Lee, Son and Lee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: SaeByul Lee, Asan Medical Center, Seoul, Republic of Korea
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.